

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A composition comprising ~~a plurality of sets of nucleic acid molecules, each set of nucleic acid molecules encoding [[a]] different type of cytomegalovirus (CMV) polypeptide polypeptides, wherein the nucleic acid molecules comprise nucleotide sequences encoding; and each molecule of a set encoding the same type of CMV polypeptide, wherein one or more sets of the plurality encodes a CMV polypeptide that induces a neutralizing antibody response, and one or more sets of the plurality encodes (a) a CMV polypeptide that induces a cell-mediated immune response, (b) a CMV polypeptide that induces a neutralizing antibody response and comprises glycoprotein B (gB) or an antigenic fragment thereof, and (c) a CMV polypeptide that induces a neutralizing antibody response and comprises a glycoprotein complex II (gCII) polypeptide or an antigenic fragment thereof; wherein the nucleic acid molecules comprise DNA plasmids.~~
2. (Canceled)
3. (Original) The composition of claim 1, wherein the CMV polypeptides are human CMV (HCMV) polypeptides.
4. (Canceled)
5. (Canceled)
6. (Currently amended) The composition of claim 1, wherein the CMV polypeptides polypeptide that ~~induce~~ induces a cell-mediated immune response ~~[[are]]~~ is selected from the

group consisting of phosphoprotein pp65 (pp65), phosphoprotein pp150 (pp150), and antigenic fragments thereof.

7. (Currently amended) A composition comprising a plurality of ~~sets of~~ nucleic acid molecules, wherein the nucleic acid molecules comprise nucleotide sequences each set encoding [[a]] different ~~type of~~ human cytomegalovirus (HCMV) polypeptide polypeptides that induces induce a neutralizing antibody response, and each nucleic acid molecule of a set encoding the same type of HCMV polypeptide wherein the HCMV polypeptides comprise: (a) glycoprotein B (gB) or an antigenic fragment thereof; and (b) a polypeptide selected from glycoprotein M (gM), an antigenic fragment of gM, glycoprotein N (gN), and an antigenic fragment of gN; wherein the nucleic acid molecules comprise DNA plasmids.
8. (Currently amended) The composition of claim 7, wherein the ~~[[CMV]] HCMV~~ polypeptides that induce an antibody response consist of: glycoprotein B and ~~glycoprotein complex II;~~ or an antigenic fragments fragment thereof; gM or an antigenic fragment thereof; and gN or an antigenic fragment thereof.
9. (Canceled)
10. (Canceled)
11. (Currently amended) The composition of claim 7, wherein the nucleic acid molecules further comprise nucleotide sequences encoding polypeptides that induce a neutralizing antibody response are selected from the group consisting of ~~glycoprotein B, gM, gN, a combination of gM and gN (glycoprotein complex II; gCII), and a combination of glycoprotein H (gH), glycoprotein L (gL), and glycoprotein O (gO) (glycoprotein complex III; gCIII) of HCMV,~~ and antigenic fragments thereof.
12. (Canceled)
13. (Canceled)

14. (Currently amended) The composition of claim [[7]] 11, wherein the polypeptides that induce a neutralizing antibody response comprise [[gcIII]] two or more of gH, gL, gO, or antigenic fragments thereof.
15. (Canceled)
16. (Canceled)
17. (Original) A pharmaceutical composition that elicits an immune response against human cytomegalovirus (HCMV) comprising the composition of claim 1 and a pharmaceutically acceptable carrier.
18. (Original) A pharmaceutical composition that elicits an immune response against human cytomegalovirus (HCMV) comprising the composition of claim 7 and a pharmaceutically acceptable carrier.
19. (Canceled)
20. (Withdrawn) A method of eliciting an immune response against human cytomegalovirus (HCMV) in a subject, the method comprising administering to the subject an amount of a pharmaceutical composition of claim 17 effective to elicit an immune response against HCMV in the subject.
21. (Withdrawn) The method of claim 20, wherein administration is by needle injection, needle-less jet injection, gene gun, topical administration, surgical administration, or mucosal administration.
22. (Withdrawn) The method of claim 20, wherein the subject is a non-human mammal or a human.
23. (Withdrawn) The method of claim 22, wherein the human is sero-negative for HCMV.
24. (Withdrawn) The method of claim 23, wherein the sero-negative human is selected from the group consisting of a female between the ages of eleven and forty, a female contemplating pregnancy, a pregnant female, an HIV-infected individual, a future organ transplant recipient, and a future bone marrow donor.

25. (Withdrawn) The method of claim 22, wherein the human is sero-positive for HCMV.
26. (Withdrawn) A kit comprising the composition of claim 1 and instructions for administration of the composition to a subject in an amount effective to treat a CMV infection.
27. (Withdrawn) The kit of claim 26, wherein the amount is effective to inhibit a future CMV infection.
28. (Withdrawn) The kit of claim 26, wherein the amount is effective to treat an existing CMV infection.
29. (Withdrawn) The kit of claim 26, wherein the composition comprises DNA plasmids.
30. (Withdrawn) A kit comprising the composition of claim 7 and instructions for administration of the composition to a subject in an amount effective to treat a CMV infection.
31. (Withdrawn) A kit comprising the composition of claim 9 and instructions for administration of the composition to a subject in an amount effective to treat a CMV infection.
32. (New) The composition of claim 1, wherein the composition comprises a plurality of sets of nucleic acid molecules, each set of nucleic acid molecules encoding a different CMV polypeptide, and each molecule of a set encoding the same CMV polypeptide.
33. (New) The composition of claim 7, wherein the composition comprises a plurality of sets of nucleic acid molecules, each set of nucleic acid molecules encoding a different HCMV polypeptide, and each molecule of a set encoding the same HCMV polypeptide.
34. (New) The composition of claim 1, wherein the gB or antigenic fragment thereof is a truncated form of gB lacking a carboxy-terminal transmembrane domain.
35. (New) The composition of claim 34, wherein the nucleic acid sequence encoding the truncated form of gB expresses a truncated form of gB in association with a tissue plasminogen activator leader sequence.

36. (New) The composition of claim 7, wherein the gB or antigenic fragment thereof is a truncated form of gB lacking a carboxy-terminal transmembrane domain.
37. (New) The composition of claim 36, wherein the nucleic acid sequence encoding the truncated form of gB expresses a truncated form of gB in association with a tissue plasminogen activator leader sequence.